

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present application.

Listing of Claims:

1-21. (Canceled)

22. (Currently Amended) An oral medicine preventing an unpleasant taste which comprises a mixture [[of]] comprising a basic medicine having an unpleasant taste and an acidic polysaccharide,

wherein the mixture is in a homogeneous blend and said basic medicine and acidic polysaccharide are in intimate contact in order to form an electric interaction and to prevent the basic medicine from dissolving in saliva;

said medicine is in the form of granules or fine granules for oral administration or a tablet for oral administration comprising the homogeneous blend;

said acidic polysaccharide is at least one selected from the group consisting of carrageenan, chondroitin sulfate, dextran sulfate and salts thereof;

said acidic polysaccharide is in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic substance having the unpleasant taste, and

said basic medicine is donepezil hydrochloride.

23-40. (Canceled)

41. **(Previously Presented)** A method for manufacturing an oral medicine ~~composition~~ in the form of granules or fine granules for oral administration or a tablet for oral administration, said medicine comprising a mixture ~~[[of]]~~ comprising a basic medicine having an unpleasant taste and an acidic polysaccharide, said method comprising:

~~blending said acidic polysaccharide with said basic medicine of donepezil hydrochloride~~
the mixture to obtain a homogeneous blend of said oral medicine composition; wherein said
acidic polysaccharide is in an amount of 0.1 to 20 parts by weight with respect to 1 part by
weight of the basic medicine; and

forming the mixture comprising the homogeneous blend into granules, fine granules or a
tablet for oral administration;

wherein said basic medicine and acidic polysaccharide are in intimate contact in order to form an electric interaction and to prevent the basic medicine from dissolving in saliva, and said acidic polysaccharide is at least one selected from the group consisting of carrageenan, chondroitin sulfate, dextran sulfate and salts thereof.

42-61. (Canceled)

62. **(Previously Presented)** The method of claim 41, wherein the acidic polysaccharide is carrageenan.

63. (Canceled)

64. (New) The oral medicine of claim 22, wherein the acidic polysaccharide is at least one selected from the group consisting of ι-carrageenan, κ-carrageenan, λ-carrageenan, dextran sulfate and a salt thereof.

65. (New) The oral medicine of claim 22, wherein said acidic polysaccharide is carrageenan.

66. (New) The oral medicine of claim 22, wherein said homogeneous blend further comprises a filler, a binding agent or disintegrant or both the filler and disintegrant.

67. (New) The method of claim 41, wherein the acidic polysaccharide is at least one selected from the group consisting of ι-carrageenan, κ-carrageenan, λ-carrageenan, dextran sulfate and a salt thereof.

68. (New) The method of claim 41, wherein the acidic polysaccharide and the basic medicine of donepezil hydrochloride are blended with a filler or disintegrant or both the filler and disintegrant to obtain said homogeneous blend.